A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Elotuzumab (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Therapeutic Use
- 24 Jun 2024 Planned End Date changed from 1 Jun 2024 to 1 Sep 2024.
- 12 Dec 2023 Results (n=541) of a secondary post-hoc analysis of SWOG Studies S0777 and S1211 assessing impact of Dexamethasone dose reductions on post-induction outcomes in subset of patients who completed all eight 3-week cycles of induction presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association